Full-Time

Senior Counsel

Global Alliance, China

Updated on 9/4/2026

AbbVie

AbbVie

10,001+ employees

Global biopharmaceutical company developing medicines

Compensation Overview

$160.5k - $305k/yr

+ Long-term incentive program

Irvine, CA, USA

Hybrid

Three days on-site per week required; the role may also be based in North Chicago, Illinois; Waltham, Massachusetts; or South San Francisco, California.

Bachelor's, Master's, JD

Category
Legal (1)

Get referred to AbbVie

See people who can refer or advise you

Requirements
  • A Juris Doctor degree and current admission to the bar in at least one U.S. state are required, along with licensure in the state where the employee will work.
  • Experience at an Am Law 100 firm or in-house at a major pharmaceutical or life-sciences company is required.
  • At least five years of relevant experience is required in life-sciences and pharmaceutical transactions; complex global collaborations and alliance governance; or pharmaceutical research, development, regulatory, manufacturing, supply, or commercialization matters.
  • Substantive knowledge of U.S.-China regulatory frameworks affecting pharmaceutical collaborations and drug development involving China is required.
  • Understanding of scientific, development, regulatory, operational, and commercial concepts in both early- and late-stage development programs is required.
  • Ability to work autonomously, take initiative, collaborate across functions and geographies, and drive successful business outcomes is required.
  • Advanced legal analysis, communication, judgment, and counseling skills are required, including the ability to identify and address critical legal and business issues promptly.
Responsibilities
  • Work with Global Alliances, R&D leadership, asset strategy teams, disease strategy teams, and other stakeholders to align legal strategy with portfolio objectives and support collaborative decision-making across the product lifecycle.
  • Advise on and track U.S.-China legal, regulatory, and policy frameworks affecting pharmaceutical collaborations and drug development involving China, including China’s Human Genetic Resources regulations, the BIOSECURE Act, DOJ Bulk Data Transfer rules, proposed outbound investment restrictions on biotechnology, U.S. and China foreign investment frameworks, and related requirements.
  • Translate legal, regulatory, and policy developments into actionable guidance for Global Alliances, R&D, regulatory, and other stakeholders.
  • Develop or support training and guidance on the applicable U.S.-China legal and regulatory frameworks.
  • Advise on alliance and collaboration matters involving China-based pharmaceutical and biotechnology partners, focusing on governance, execution, and long-term partnership value.
  • Interpret and analyze strategic agreements, including licenses, collaborations, co-development arrangements, and other alliances, and provide legal advice on partnered R&D, manufacturing, supply, and commercialization activities.
  • Draft, review, and negotiate amendments, governance documents, dispute resolutions, operational agreements, and other documents supporting the post-execution lifecycle of strategic collaborations.
  • Collaborate with the Transactions Legal team and business development to evaluate, structure, and negotiate new collaborations with China-based counterparties, including deal structuring, due diligence, risk assessment, drafting, and integration planning.
Desired Qualifications
  • Nine or more years of relevant experience is preferred.
  • Experience with China-based pharmaceutical or biotechnology collaborations, cross-border life-sciences transactions, or global alliance management is strongly preferred.
  • Mandarin Chinese proficiency is preferred.
  • Scientific background through undergraduate or graduate education in the sciences, or a demonstrated interest in learning the fundamentals of biology, chemistry, and drug development, is preferred.

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $16.99 billion, up 10.2%, with EPS of $3.65.
  • Apogee acquisition adds late-stage eczema and asthma assets, closing in Q3 2026.
  • Rinvoq gained EU vitiligo and alopecia areata approvals in 2026, expanding peak sales.

What critics are saying

  • Skyrizi and Rinvoq generated 42% of 2025 revenue, concentrating execution risk.
  • Imbruvica sales fell 29.4% in Q2 2026, proving oncology weakness.
  • A failed Apogee integration or weaker dermatology data would shrink 2026 earnings.

What makes AbbVie unique

  • Skyrizi and Rinvoq drove $8.03 billion in Q2 2026 revenue.
  • AbbVie owns a broad immunology pipeline, including Apogee's APG777 and APG273.
  • AbbVie still pairs pharmaceuticals with Allergan aesthetics, including SKINVIVE and Botox.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

5%

1 year growth

5%

2 year growth

5%
INSURASALES
Sep 5th, 2026
Manufacturers Life Insurance buys $655M stake in AbbVie as institutions boost pharma holdings

The Manufacturers Life Insurance Company acquired a $655.27 million stake in AbbVie Inc., according to its latest SEC Form 13F filing. Other institutional investors also increased their positions significantly during the same period. Norges Bank acquired a new $5.87 billion position, whilst Wellington Management Group boosted its holdings by 457.4%. AbbVie reported quarterly earnings per share of $3.65, exceeding forecasts, with revenue growth of 10.2% year over year. The company generated $16.99 billion in revenue last quarter, surpassing expectations. Equity analysts maintain a bullish outlook. Barclays, Wolfe Research, and BMO Capital Markets each set price targets of $300, with ratings of "overweight" or "outperform". The consensus rating is "Moderate Buy". Institutional investors currently hold 70.23% of AbbVie's shares, reflecting confidence in the biopharmaceutical company's strategy and performance.

PharmTech
Sep 4th, 2026
AAPS PharmSci 360: CMC strategies, part 1.

AAPS PharmSci 360: CMC strategies, part 1. In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discussed how CMC review practices are evolving and what that means for manufacturing strategy. PharmTech spoke with Alfred Rumondor, PhD, CMC due diligence for external assets at AbbVie, and Swita Singh, PhD, Senior Director and Strategic CMC Leader at Bristol Myers Squibb, to learn more about their upcoming panel discussion, Navigating CMC Strategy in the Current Landscape, at, which is being held from October 25-28 in New Orleans. In part 1 of this 3-part interview, Rumondor and Singh discussed how chemistry, manufacturing, and controls (CMC) review practices are evolving and what that means for manufacturing strategy. Singh identified the most consequential shift as a move from informal, reviewer-dependent flexibility to formal, risk-based flexibility applied consistently across the product life cycle. She pointed to Operation TrailBlazer and updated phase 1 CMC guidance as examples, stating they are reducing required manufacturing data pre-investigational new drug application (IND). Singh also pointed out that cell and gene therapy programs no longer need 3 independent process performance qualification batches and can flex specifications for small-batch production. AI-driven tools and emerging credibility frameworks are reinforcing this trend by helping generate cleaner data packages for faster, more consistent regulatory decisions. Singh cautioned, however, that companies must build "risk justification muscle" rather than simply accepting flexibility at face value. Reduced requirements should be treated as deferral, not elimination, of data obligations; organizations need clear plans for when deferred data will be generated and which milestones trigger it. She emphasized investing early in comparability infrastructure, leveraging platform and prior-knowledge pathways, and engaging proactively with regulators. Rumondor addressed the pressure to compress development timelines. He argued the real question isn't whether compression is safe, but how to do it properly by working smarter rather than skipping steps. He cited premature form selection without adequate screening as a common shortcut that later may bring costly bridging and comparability studies, increasing both timeline and program risk. Compressed timelines are achievable, but only when teams rigorously plan the full development path upfront, according to Rumondor. About the speakers. Alfred Rumondor, PhD, is Director, Development Sciences Licensing and Acquisitions, at AbbVie. Dr. Swita Singh holds a Ph.D. in Pharmaceutical Sciences and brings over fifteen years of distinguished expertise in Chemistry, Manufacturing, and Controls (CMC) development across biologics, antibody drug conjugates, and small molecules, with a proven record of driving strategic initiatives, optimizing complex business processes, and leading cross-functional teams to achieve regulatory and operational excellence. Recognized for delivering innovative, end-to-end CMC strategies that guide programs from early clinical development through successful commercialization, she has cultivated talent and shaped organizational culture throughout her career, while her commitment to stakeholder communication and cross-functional collaboration has consistently advanced program objectives across the industry. Having built her expertise at Pfizer and Eli Lilly and Company, Dr. Singh currently serves at Bristol Myers Squibb (BMS), where she continues to lead CMC strategy in support of transformative therapeutic development.

Yahoo Finance
Sep 3rd, 2026
AbbVie's etentamig shows 74% response rate in cancer trial, beating standard treatment by 28 percentage points

AbbVie's experimental cancer drug etentamig achieved a 74% overall response rate in a pivotal Phase 3 trial for relapsed or refractory multiple myeloma, significantly outperforming standard treatments at 45.7%. The study also met its progression-free-survival endpoint. The drug remains investigational pending regulatory review. AbbVie's oncology division reported $1.65 billion in second-quarter revenue, down 1.5%, representing roughly 9.7% of total sales. Venclexta grew 11.6%, whilst Imbruvica declined 29.4%. AbbVie shares traded at $260.445. The company requires new growth drivers as its existing oncology portfolio faces mixed performance. Detailed safety and durability data have not yet been disclosed.

Yahoo Finance
Sep 3rd, 2026
J&J rises 1% as AbbVie's myeloma drug shows 74% response rate

Johnson & Johnson shares rose roughly 1% to $277.96 Thursday after AbbVie announced its experimental multiple-myeloma drug, etentamig, achieved a 74% response rate and reduced the risk of disease progression or death by 60% compared to standard therapies. AbbVie's trial positions a convenient monthly treatment in the myeloma market for potential outpatient use. However, J&J is defending its growing franchise, with Carvykti driving 6.8% operational growth in Innovative Medicine during the second quarter. According to Reuters, etentamig appears most differentiated after CAR-T therapy rather than as a direct Carvykti substitute. The market is treating AbbVie's advancement as category expansion rather than a direct threat to J&J. J&J's current share price stands 44.08% above its $192.92 valuation estimate, making future safety and durability data critical for investors.

Yahoo Finance
Aug 29th, 2026
AbbVie acquires Apogee for $10.9B as Eli Lilly's GLP-1 drugs drive 45% revenue surge

AbbVie is acquiring Apogee Therapeutics for approximately $10.9 billion as it works to diversify beyond its core immunology portfolio. The pharmaceutical giant reported revenue of nearly $61.2 billion in FY 2025, up roughly 8.7% year-on-year, with Skyrizi and Rinvoq accounting for about 42% of sales. Eli Lilly achieved sharper growth, with revenue reaching nearly $65.2 billion in FY 2025, a 45% increase driven by GLP-1 drugs Mounjaro and Zepbound. These therapies represented roughly 56% of total revenue. Net income was approximately $20.6 billion. AbbVie's balance sheet shows a debt-to-equity ratio of negative 21x, whilst Eli Lilly's stands at roughly 1.6x. Free cash flow was nearly $17.8 billion for AbbVie and close to $9.0 billion for Eli Lilly.